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Abstract This review discusses available literature on the
diagnosis and management of intrauterine growth restriction
(IUGR) in women with type 1 diabetes. IUGR is diagnosed
when ultrasound-estimated fetal weight is below the 10th per-
centile for gestational age. IUGR diagnosis implies a patho-
logic process behind low fetal weight. IUGR in pregnancy
complicated by type 1 diabetes is usually caused by placental
dysfunction related to maternal vasculopathy. Prevention of
IUGR should ideally start before pregnancy. Strict glycemic
control and intensive treatment of nephropathy and hyperten-
sion are essential. Low-dose aspirin initiated before 16 gesta-
tional weeks can also reduce IUGR risk in women with vas-
culopathy. Umbilical and uterine artery Doppler studies can
guide diagnosis and surveillance of fetuses with IUGR.
Decisions regarding the timing of delivery should be based
on assessment of umbilical artery Doppler. The risk of prema-
turity and impaired fetal lung maturation should always be
considered, especially in fetuses younger than 32 weeks.
Keywords Intrauterine growth restriction . IUGR . Small for
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Introduction
Fetal growth is a result of complex interactions between the
genetic growth potential of the fetus and the impact of the
maternal intrauterine environment. Causes of intrauterine
growth restriction (IUGR) are generally classified as maternal,
fetal, or placental. However, such distinction is rather theoret-
ical, as these factors often overlap each other.
Impaired fetal growth not only results in elevated risk for
short-term complications, with intrauterine fetal death being
the most severe, but low birth weight also predisposes the
child to cardiovascular disease and type 2 diabetes mellitus
in the future [1, 2].
IUGR is a common cause of iatrogenic prematurity, as a
manifestation of ischemic placental disease—a syndrome of
placental insufficiency found in several pregnancies terminat-
ed prematurely due to fetal conditions.
IUGR is diagnosed when ultrasound-estimated fetal weight
is below the 10th percentile for gestational age. A diagnosis of
IUGR implies a pathologic growth restriction responsible for
low fetal weight [3–5]. Small for gestational age (SGA) is
another term that defines a fetus with an estimated weight
below the 10th percentile; however, the term SGA does not
imply a pathological condition causing low fetal weight.
Approximately 70 % of SGA fetuses are constitutionally
small, meaning they are small but healthy. The remaining
are fetuses with IUGR, which are at high risk for peri-
natal complications and therefore require more intensive
surveillance [6•].
Fetal growth abnormalities are frequently seen in diabetic
pregnancy, with large for gestational age (LGA) being the
most typical one. LGA has been widely studied and seems
to be associated most frequently with maternal hyperglyce-
mia, although other factors such as gestational weight gain
and maternal lipids may also play a role [7–12]. However,
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diabetic pregnancy can also be associated with restricted fetal
growth. Long-standing and poorly controlled type 1 diabetes
represents a wide spectrum of clinical conditions, mostly re-
lated to diabetic vasculopathy. Since the placenta is an organ
composed almost entirely of vessels, maternal vasculopathy
can be linked to placental dysfunction and subsequent fetal
growth restriction [13–15].
The incidence of type 1 diabetes is rising at an alarming
rate, particularly in younger age groups. Although disease
outcomes have been improving over the past decades,
resulting in a reduction in total mortality, these beneficial
trends start to disappear for the incidence of nephropathy
and proliferative retinopathy at 20 years of diabetes duration
[16]. Thus, it may be expected that an increasing number of
women with diabetic vascular disease are now, or soon will
be, entering childbearing age. IUGR could therefore become
one of the major pregnancy complications exacerbated by
type 1 diabetes.
This review discusses available literature on the diagnosis
and management of IUGR in women with type 1 diabetes.
However, data on IUGR in type 1 diabetic pregnancy is lim-
ited and there are no randomized controlled trials on the man-
agement of IUGR in this group of patients. This significantly
limits the strength of the evidence. Therefore, we discuss
existing guidelines for a normal population in the context of
diabetic pregnancy and focus on expert opinion as well as our
personal experience regarding the management of diabetic
pregnancy.
Pathogenesis of IUGR in Pregnancy Complicated
by Type 1 Diabetes—the Key Role of Diabetic
Vasculopathy
Many factors can potentially interfere with genetically
predetermined fetal growth causing its restriction. In this sec-
tion, we provide an overview of maternal and placental factors
related to diabetes that cause IUGR.
The incidence of type 1 diabetes peaks in 10–14 year
olds and is rising at an alarming rate worldwide, partic-
ularly in younger age groups (0–4 years) [17]. Many of
these girls are reaching childbearing age as women with
long-standing diabetes, frequently complicated by
vasculopathy.
Metabolic alterations associated with diabetes impact the
development and function of utero-placental and feto-
placental units from the beginning of pregnancy. Fetal growth
in type 1 diabetic pregnancy might be altered in two opposing
ways. Maternal hyperglycemia stimulates fetal overgrowth,
while maternal vasculopathy can be associated with placental
insufficiency leading to altered nutrient transport and subse-
quent IUGR.
Histopathological Studies
Several histopathological changes can occur in the placenta in
response to a diabetic environment [18]. Although some of
them are not specific for the diabetic placenta, maternal arte-
rial malperfusion, distal villus maldevelopment, and fetal vas-
culitis might be considered characteristics for diabetic pla-
centas. Maternal arterial malperfusion occurs as a conse-
quence of inadequate and incomplete invasion of the tropho-
blast and deficient spiral artery transformation [19].Moreover,
unremodeled uterine arteries can additionally present features
of decidual vasculopathy. It has been previously shown that
almost a quarter of type 1 diabetic placentas harbored decidual
vasculopathy [20]. These pathological changes are associated
with IUGR, particularly in preeclamptic women [19, 21].
Women with type 1 diabetes are at substantially higher risk
of preeclampsia. Furthermore, the risk increases with longer
diabetes duration, with the highest rates reported in women
with diabetic nephropathy, placing them at the highest risk of
developing IUGR [22]. Distal villus maldevelopment is a term
representing a group of histopathological findings including
distal villous hypoplasia, distal villous immaturity,
chorangiosis, and dysmorphic villi. These changes are associ-
ated with the reduction of functional villus surface area and
can be observed in a significant proportion of IUGR placentas
[23, 24]. Fetal vasculitis is a common histopathological find-
ing in diabetic placentas and might be a marker of fetal in-
flammatory response [20, 25]. The role of fetal vasculitis in
IUGR remains unknown; however, some authors reported an
association between different markers of inflammatory state
and IUGR [26, 27].
Biochemical Studies
Abnormalities in placental angiogenesis due to maternal mi-
croangiopathy have their roots early in pregnancy. It has been
demonstrated that placental growth factor (PlGF) concentra-
tion dynamics is impaired in women with type 1 diabetes
whose fetuses later develop SGA. While PlGF serum concen-
tration doubled between the first and second trimesters in
women with type 1 diabetes who delivered newborns with
normal growth, there was no physiological increase in PlGF
in the SGA group. Importantly, the majority of women from
the SGA group had some form of diabetic vasculopathy [13].
Other interesting findings come from a study on markers of
endothelial dysfunction. Zawiejska et al. observed elevated
maternal serum concentration of vascular cell adhesion
molecule-1 (VCAM-1) in early gestation and low levels in
late gestation in women with type 1 diabetes who gave birth
to SGA newborns. The authors hypothesized that observed
changes may be a manifestation of endothelial injury in early ges-
tation followed by placental dysfunction in late gestation. Early
vascular dysfunction was also proposed as a major factor involved
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in preeclampsia inwomenwith type 1 diabetes. The authors of this
study demonstrated significantly increased first trimester serum
levels of VCAM-1 and intercellular adhesion molecule-1
(ICAM-1) in the preeclamptic group [28].
Doppler Ultrasound Findings
Although placental histopathological findings provide sub-
stantial and clinically relevant information, these data are al-
ways retrospective and represent pathological processes and
adaptations that have been taking place sometimes many
weeks before delivery. Doppler ultrasound enables the real-
time assessment of placental and fetal circulation and has been
widely used in the monitoring of high-risk pregnancies.
Moreover, abnormal umbilical and uterine Doppler velocity
waveforms in IUGR have been correlated with abnormal pla-
cental pathology [29–31]. Efficient utero-placental and feto-
placental circulation is crucial for the maintenance of physio-
logical fetal growth. Pietryga et al. demonstrated significantly
increased uterine artery vascular impedance in pregnant wom-
en with type 1 diabetes with vasculopathy [32]. Furthermore,
increasing uterine artery scores were associated with an in-
creasing proportion of SGA newborns. In this study, abnormal
uterine Doppler was almost exclusively seen in women with
classes R/F retinopathy and nephropathy, according to White
[33]. Women with uncomplicated diabetes or isolated retinop-
athy had relatively normal Doppler results. The proportion of
abnormal flow in umbilical arteries was significantly lower
and unrelated to vasculopathy. This suggests that impairment
of utero-placental circulation is a primary pathology in the
placentas of women with severe vasculopathy and changes
in the umbilical artery may occur later as an adaptation to
reduced utero-placental perfusion. Impairment of placental
function in diabetic vasculopathy has been directly confirmed
in a study by Salvesen et al. It was conducted in a cohort of 41
women with type 1 diabetes undergoing cordocentesis up to
24 h before delivery. The authors found that all fetuses of
women with nephropathy and hypertension had significantly




Because IUGR is associated with unfavorable perinatal out-
comes and therefore has a strong impact on the management
of pregnancy, it should be clearly distinguished from consti-
tutional small for gestational age (cSGA). The most widely
used definition of IUGR is based on the estimated fetal weight
(EFW) below the 10th percentile [3–5]. However, according
to the Royal College of Obstetricians and Gynecologists
(RCOG), the diagnosis of IUGR can also be made on the basis
of fetal abdominal circumference (AC) below the 10th percen-
tile [4]. The brief summary of diagnostic criteria as well as
important aspects on the management of IUGR is summarized
in Table 1. It should be mentioned that percentile charts used
for these determinations were developed based on the healthy
population. Persson et al., in their large population-based co-
hort study, showed that distribution of birth weight (BW) of
offspring born to the mothers with type 1 diabetes was signif-
icantly wider and shifted to the right of the normal reference.
Moreover, newborns of the mothers with type 1 diabetes had
higher mean BW despite significantly lower mean gestational
age (GA) at birth [35]. Similar findings have been demonstrat-
ed by others in smaller cohorts [36, 37]. However, Howart et
al. showed that such distribution is rather a characteristic for
uncomplicated type 1 diabetic pregnancy. These authors dem-
onstrated that customized BW percentiles of newborns of
women with vascular disease (defined as the presence of at
least one of the following: diabetic retinopathy, diabetic ne-
phropathy, or preexisting hypertension) were bimodally dis-
tributed [38]. The authors concluded that coexistence of dia-
betes and vascular disease produces an evenmore unfavorable
intrauterine environment, which may falsely Bnormalize^ the
growth of fetuses destined to develop macrosomia. One may
suggest that among these fetuses, some could be growth re-
stricted due to impaired placental function and Bnormalized^
by maternal hyperglycemia. These facts raise the question
whether the diagnosis of IUGR in women with type 1 diabetes
is appropriate using charts based on a healthy population. This
question still remains open, as there is no evidence in the
literature to support different diagnostic approaches.
Therefore, the diagnosis of IUGR in women with type 1 dia-
betes should be based on the same criteria as for the reference
population. Nonetheless, special attention should be paid to
fetuses with borderline estimated fetal weight, as the risk for
false negative diagnosis may be increased due to changes in
their weight distribution. In suspicious or questionable cases,
uterine and umbilical artery Doppler ultrasound may provide
useful diagnostic information, especially when IUGR is of
placental origin in women with diabetic vasculopathy [32,
39].
Importance of Pregnancy Dating
Accurate pregnancy dating is essential for the diagnosis of
IUGR. However, estimation of GA based on the last menstrual
period (LMP) might be inadequate in a significant proportion
of women with type 1 diabetes due to frequent menstrual
irregularities [40, 41].
Measurement of crown-rump length (CRL), optimally be-
tween weeks 9 and 13 of gestation, provides the most reliable
basis for further evaluation of fetal growth and should be
precisely documented in women with type 1 diabetes [42, 43].
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Early Detection of Women at Risk
Detection of patients at risk of IUGR should ideally start early
in the pregnancy. In addition to traditional medical and obstet-
ric risk factors for IUGR, women with type 1 diabetes should
be screened for vascular disease, primarily nephropathy [14,
38]. Notably, not only overt nephropathy but also
microalbuminuria has been associated with IUGR [15].
Despite the known association between diabetic retinopathy
and adverse pregnancy outcomes, there are no studies directly
linking diabetic retinopathy to IUGR [44, 45]. One study re-
ported no difference in the incidence of fetal growth restriction
between women with microvascular complications (retinopa-
thy and nephropathy, analyzed together) and those without
them [46]. This might be attributed to the significant improve-
ments in the quality of care in pregnant women with type 1
diabetes, particularly intensification of antihypertensive treat-
ment [47•].
Diabetes, especially when uncontrolled early in pregnancy,
increases the risk of fetal structural anomalies which may also
manifest as impaired fetal growth [48, 49]. IUGR fetuses
should therefore undergo detailed anatomy scans involving
echocardiography.
Management of IUGR
IUGR increases the risk of adverse pregnancy outcomes in-
cluding preterm delivery, intrauterine fetal death (IUFD), neo-
na ta l dea th , low APGAR scores , and abnormal
neurodevelopment of the child [50, 51]. Thorough prenatal
surveillance and appropriate timing of delivery can reduce
the risk of perinatal mortality and morbidity in women with
type 1 diabetes.Womenwith pregnancies complicated by type
1 diabetes and IUGR should be managed by maternal-fetal
medicine specialists experienced in the field of diabetic preg-
nancy at a perinatal center with access to a neonatal intensive
care unit.
Ultrasound Surveillance
Ultrasound biometry is essential for the diagnosis of IUGR
due to its superiority in clinical weight estimation using fundal
height measurements. Therefore, it seems reasonable to per-
form ultrasound biometry in all women with risk factors for
fetal growth abnormalities, including those with diabetes.
IUGR associated with diabetic vasculopathy and resultant pla-
cental insufficiency is typically asymmetric and does not man-
ifest before the third trimester [52]. Symmetric growth restric-
tion diagnosed earlier in the second trimester raises the suspi-
cion of genetic disorders or congenital malformations and
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Subsequent serial ultrasoundmeasurements provide further
information on fetal growth pattern, which might be altered in
women with type 1 diabetes [52]. The optimal intervals be-
tween scans have not been determined and should be based on
individual clinical judgment. However, it is suggested that
repeated measurements should be performed at least 3 weeks
apart to reduce the possibility of a false positive diagnosis [3,
4]. There is no evidence to support more frequent fetal biom-
etry in women with type 1 diabetes and IUGR.
Amniotic fluid volume (AFV) assessment is a routine part
of ultrasound scanning during pregnancy. Although,
oligohydramnios is associated with SGA and perinatal mor-
tality, its predictive value for individual risk for the outcome is
poor [53]. Thus, AFV measurement should not be used as the
only method of monitoring IUGR fetuses. However, in con-
junction with Doppler studies or as a part of biophysical pro-
files (BPP), it can provide more clinically relevant information
on fetal well-being. AFV can be assessed by subjective (based
on the examiner’s visual assessment) and objective (amniotic
fluid index [AFI] and single deepest pocket [SDP]) methods.
It is recommended to measure AFV objectively when either
subjective measurements suggest decreased AFV or in pa-
tients with higher risk of IUGR. Comparison of AFI and
SDP revealed that AFI was associated with higher rates of
false positive diagnosis of oligohydramnios which may lead
to unnecessary labor induction [54]. Thus, SDP measurement
may be preferred over AFI, especially in preterm pregnancies.
Although there are no randomized trials examining the
utility of ultrasound Doppler surveillance in pregnancy com-
plicated by type 1 diabetes, existing evidence from observa-
tional studies support this method as the best for detection of
fetal distress in high-risk pregnancies, including IUGR.
Doppler ultrasound directly reflects impairment of utero-
placental and feto-placental circulation which is, in the case of
IUGR, related to maternal vasculopathy [32, 39]. In addition
to its essential role in determining the cause of fetal growth
restriction (placental insufficiency vs. constitutional SGA/
other causes), umbilical Doppler velocimetry has been widely
recommended as a main method for the follow-up of IUGR
fetuses [3–5]. In pregnancy complicated by type 1 diabetes,
umbilical artery Doppler velocimetry was found to be superior
to non-stress test and BPP in identifying fetuses at risk of
adverse outcome [55]. In normal circumstances, in the second
part of pregnancy, umbilical and uterine arteries are low-
resistance vessels. In cases of placental dysfunction, both ves-
sels can present features of increasing flow resistance. These
alterations are manifested in Doppler as increasing pulsation
index (PI), the presence of end-diastolic notches in uterine
arteries, and increasing PI in umbilical arteries. Increasing
resistance in umbilical arteries can cause severe hemodynamic
changes which can be further manifested as absent end-
diastolic velocity (AEDV) and reversed end-diastolic velocity
(REDV).
Biophysical Profile (BPP) and Fetal Heart Rate
Monitoring
The number of studies on the utility of BPP and fetal heart rate
monitoring (FHRM) in pregnancy complicated by type 1 dia-
betes is limited [34, 55, 56]. It was shown that both BPP and
FHRM had lower predictive value of adverse pregnancy out-
comes including fetal growth restriction than umbilical artery
Doppler [55] and their results were not predictive for fetal
acidemia [34]. The low predictive value of abnormal BPP
has been confirmed in a prospective study using multiple
BPP from 28 weeks until delivery [56]. Nonetheless, the high
predictive value of normal BPP makes it a more valuable tool
for surveillance of fetuses at high risk of IUFD, including
these with IUGR. However, it should be remembered that
diabetes may have an impact on the results of BPP as maternal
hyperglycemia was found to increase both fetal respiratory
movements and AFV [57, 58]. Furthermore, sustained hyper-
glycemia (>120 mg/dL) was associated with a decrease in
fetal movements in healthy women [59]. No significant
changes in fetal body and respiratory movements were ob-
served during hypoglycemia [60].
Maternal Perception of Fetal Movements
Decreased fetal movements (DFM) perception in the third
trimester has been associated with increased rates of IUGR,
emergency cesarean section (CS), and IUFD [61]. There are
no separate guidelines on the management of DFM in women
with type 1 diabetes. Nonetheless, reports of DFM should
always prompt further investigation, including confirmation
of fetal heart rate and weight estimation by ultrasound. If the
fetus is found to be IUGR, umbilical and uterine Doppler
should be considered due to the high risk of placental dysfunc-
tion, primarily in women with vasculopathy [32].
Diet and Physical Activity
There is no evidence that changes in diet or supplement use
can prevent or treat IUGR. Thus, individualized medical nu-
trition therapy (IMT) for pregnant women with type 1 diabetes
is indicated. IMT is aimed at achieving glycemic targets and
maintaining appropriate gestational weight gain [62].
There is no evidence to recommend bed rest as a method of
either prevention or treatment of IUGR [63]. However, stren-
uous physical activity should be avoided due to risk of
hypoglycemia.
Glycemic Targets and IUGR
There is no evidence to support the use of individualized gly-
cemic targets in pregnant women with type 1 diabetes and
IUGR. Nonetheless, Langer et al. showed in women with
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gestational diabetes mellitus (GDM) that had low levels of
mean glycemia throughout pregnancy (<86 mg/dL) were as-
sociated with a significant increase in SGA in comparison to
healthy controls (20 vs. 11 %) [64]. To the authors’ knowl-
edge, there are no similar studies in women with type 1 dia-
betes and IUGR. However, it could be hypothesized that too
strict glycemic control in women with already impaired pla-
cental function and diminished nutrient transport to the fetus
could cause further restriction of fetal growth with all associ-
ated complications [65].
Antenatal Corticosteroids
IUGR is associated with significantly increased rates of pre-
term deliveries, primarily iatrogenic. Diabetes is not consid-
ered a contraindication for the administration of corticoste-
roids for fetal lung maturation, but this procedure should be
precisely planned with increased dosages of insulin [66].
There is no full consensus on the time window when cortico-
steroids should be given in pregnancies complicated by
IUGR. The American College of Obstetricians and
Gynecologists (ACOG) and the Society of Obstetricians and
Gynaecologists (SOGC) recommend a single course of corti-
costeroids when there is a significant risk of delivery
<34 weeks of gestation [3, 5]. The RCOG recommends that
in pregnancy with fetal growth restriction and anticipated pre-
term delivery, a single course of corticosteroids should be
given until 35+6 weeks of gestation [4].
However, the strongest evidence exists for supporting the
use of corticosteroids until 34+6 weeks [67]. Furthermore,
bearing in mind that high doses of potent corticosteroids
(betamethasone or dexamethasone) can significantly deterio-
rate maternal glycemic control, it seems reasonable to recom-
mend stimulation for fetal lung maturation until 34+6 weeks
in women with type 1 diabetes. Treatment with corticosteroids
should be followed by appropriate insulin dose adjustment
and frequent glycemic monitoring [68, 69].
Timing and Mode of Delivery
The aim of intensive surveillance of the fetus with IUGR is
to detect the safest time for delivery. This is often difficult
for even the most experienced obstetrician, especially in
cases of fetal prematurity. Thus, several factors should be
taken into careful consideration while making a decision
on timing and mode of delivery for IUGR fetus.
Management always depends on the etiology of IUGR. In
women with type 1 diabetes, IUGR is typically of placental
origin. Undoubtedly, this is the most difficult to manage
and most unpredictable type of IUGR, especially in women
with nephropathy and preeclampsia. In such cases, the de-
cision on timing of delivery is often based on either signs
of acute fetal distress, deterioration of maternal state, or
both. There are several tools for fetal surveillance; howev-
er, only some have been proven to predict neonatal out-
comes. None of them have been studied exclusively in
women with type 1 diabetes and IUGR in the context of
timing of delivery. Doppler velocimetry is considered the
most sensitive method to detect risk of fetal death.
Although several vessels can be examined during this pro-
cedure, only umbilical artery velocimetry has been found
to decrease the likelihood of perinatal deaths in IUGR [70].
Therefore, it is recommended to base the decision regard-
ing timing of delivery on the results of umbilical artery
Doppler studies (absent or reversed end-diastolic velocity
[AREDV]) [3, 5, 70]. Nonetheless, GA is the major deter-
minant of fetal survival in IUGR diagnosed before
33 weeks [71]. RCOG recommends that in fetuses with
AREDV detected prior to 32 weeks, delivery should be
considered when either ductus venosus (DV) abnormalities
or umbilical vein (UV) pulsation is found [4].
The IUGR itself is not an indication for CS. However, a
significant number of IUGR fetuses is delivered via urgent
CS due to acute signs of fetal distress demonstrated either
before the onset of spontaneous contractions (umbilical
artery AREDV, UV pulsation, DV abnormalities) or
intrapartum (late or variable decelerations, loss of fetal
heart rate variability). IUGR of placental origin is a mani-
festation of chronic fetal distress, and the fetus may already
be acidotic. Blood flow throughout the placenta decreases
during contractions, which may result in metabolic decom-
pensation of the fetus. Thus, it seems reasonable to recom-
mend the use of continuous FHRM during labor in women
with type 1 diabetes and IUGR from the onset of contrac-
tions [4]. Vaginal delivery of a fetus with umbilical artery
AREDV is not recommended and CS is necessary even in
very premature periods [4].
Maternal Interventions and Preventive Strategies
IUGR due to placental insufficiency is a progressive and irre-
versible disease. Except for intensive prenatal surveillance
aimed at establishing appropriate timing of delivery, there
are no perinatal interventions proven to be associated with
improved outcomes of IUGR fetuses. Therefore, the question
arises whether IUGR might be somehow prevented in women
with type 1 diabetes. Although limited conclusions can be
made regarding the prevention of IUGR in women with type
1 diabetes complicated by vasculopathy, pregnancy planning
and appropriate management of vascular complications and
hypertension could play an important role. While poor glyce-
mic control in the second part of pregnancy stimulates fetal
overgrowth, it can exert the opposite effects in early pregnan-
cy by affecting early placental development. Evidence
supporting this association comes from studies linking poor
glycemic control in early pregnancy to preeclampsia [72, 73].
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IUGR is one of the major complications of preeclampsia, and
there is a strong evidence that they share common pathophys-
iology [74–76]. Thus, interventions that have been found to
reduce the risk of preeclampsia can also reduce the risk of
IUGR. Low-dose aspirin (50–150 mg) administered at or be-
fore 16 weeks of pregnancy has been found to reduce the risk
of both [77]. However, there is no consensus on the use of
aspirin for prevention of IUGR. The SOGC recommends low-
dose aspirin use in high-risk patients, including women with
pregestational diabetes and women with a previous history of
IUGR or preeclampsia [5]; however, the ACOG and RCOG
do not due to lack of evidence for its preventative effects for
IUGR [3, 4]. The ACOG and RCOG do, however, recom-
mend its use in patients at high risk of preeclampsia. It is well
known that the presence of even mild diabetic nephropathy is
one of the strongest determinants of preeclampsia [22, 78, 79].
It is therefore reasonable to recommend low-dose aspirin from
12 gestational weeks for women with type 1 diabetes with
vascular disease, primarily nephropathy, for the prevention
of preeclampsia and associated complications, including
IUGR [47•]. Moreover, early introduction of intensive antihy-
pertensive treatment in women with type 1 diabetes with ne-
phropathy may alleviate the severity of preeclampsia and in-
crease the chances for normal fetal growth [14, 80]. Treatment
should be initiated when blood pressure (BP) exceeds 135/
85 mmHg or urinary albumin excretion exceeds 300 mg/
24 h. Less rigorous therapeutic targets (BP >140/90 mmHg
or albuminuria >2000 mg/24 h) have been associated with an
increased rate of preeclampsia and preterm delivery [80].
Conclusion
IUGR in pregnancy complicated by type 1 diabetes is usually
the result of placental dysfunction related to maternal vascu-
lopathy. Strict glycemic control and intensive hypertension
treatment before and during pregnancy can potentially reduce
the risk of IUGR in women with type 1 diabetes by improving
placental function. Low-dose aspirin initiated at 12 weeks of
gestation may be beneficial for women with type 1 diabetes at
risk of IUGR, primarily those with diabetic nephropathy.
Management of IUGR should focus on early diagnosis and
intensive prenatal surveillance using ultrasound. Umbilical
and uterine artery Doppler can be useful in the diagnosis and
monitoring of fetuses with IUGR. Decisions regarding the
timing of delivery should be based on the assessment of um-
bilical artery Doppler (the presence of AREDV). However, in
fetuses with AREDV detected prior to 32 weeks, delivery
should be considered when either DV abnormalities or UV
pulsation is found. When preterm delivery is anticipated, an-
tenatal steroids should be administered until 34+6 weeks of
gestation.
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